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Abstract 
We investigated the potential usefulness of vesnarinone, a novel cytokine inhibitor, for the 
treatment of lung fibrosis using a murine model of bleomycin (BLM)-induced pulmonary fi-
brosis. Mice were fed a control diet (n=42), or a diet containing low (n=42) or high (n=42) 
dose of vesnarinone. Dietary intake of vesnarinone minimized the BLM toxicity as reflected 
by significant decreases in numbers of inflammatory cells, KC, and soluble TNF receptors in 
the bronchoalveolar lavage fluid. A quantitative evaluation of histology demonstrated sig-
nificantly mild lung parenchymal lesions in BLM-treated mice fed with diet containing high 
dose of vesnarinone than in the control diet group. Consistent with the histopathology, hy-
droxyproline levels in lung tissue from BLM-treated mice fed with diet containing vesnari-
none were significantly lower than that from mice fed with control diet. We concluded that 
vesnarinone inhibits BLM-induced pulmonary fibrosis, at least in part, by the inhibition of 
acute lung injuries in the early phase. 
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Introduction 
Pulmonary fibrosis is an intractable paranchy-
mal lung disease characterized by persistent alveoli-
tis, accumulation of connective tissue and extracellu-
lar matrix [1-4]. The pathogenesis of pulmonary fi-
brosis is not well elucidated. Since the pathological 
changes of alveolitis and fibrosis are similar to pul-
monary fibrosis seen in humans, bleomycin (BLM) 
models of pulmonary fibrosis have been investigated 
in various animal species with different routes of 
administration [4-6]. Although a variety of drugs, 
compounds, and antibodies have been investigated 
for their effectiveness, few showed clinical efficacy for 
preventing the development of pulmonary fibrosis 
[1-6].  
Vesnarinone is a quinolinone derivative, and its 
pharmacodynamic effects include inhibition of 
phosphodiesterase III (PDE3) activity, increases in 
calcium flux and decreases in potassium flux [7-9]. 
Recently, a novel cytokine-inhibiting activity of 
vesnarinone has been focused attention, because of 
the potential mechanisms by which vesnarinone re-
duces mortality in a murine model of myocarditis [10] 
or lethal endotoxemia [11]. Indeed, several in vitro 
studies have shown that vesnarinone suppresses the Int. J. Biol. Sci. 2009, 5 
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production of TNF-α and IL-6 in various human cell 
lines, including peripheral lymphocytes, monocytes, 
and T-cell lines [12]. Moreover, an in vivo study of 
endotoxemia in rabbits showed that IV vesnarinone 
reduced the circulating levels of TNF-α [13]. Cumula-
tive evidence showed that a variety of cytokine are 
involved in the pathogenesis of pulmonary fibrosis 
[3]. Thus, we investigated the effects of oral intake of 
vesnarinone on the development of pulmonary fibro-
sis in BLM-induced lung injury in mice. 
Material and Methods 
Animals and Animal Treatments 
Male ICR mice, 8 to 10 weeks of age, were pur-
chased from Japan Clea Co. (Tokyo Japan). These 
animals were divided into the six groups, as shown in 
table 1. Vesnarinone (Otsuka Pharmaceut. Comp. 
Tokushima, Japan) were added to the diet. From the 
daily food intake of mice, we estimated the content of 
vesnarinone at 100 mg/kg/day (groups L and LB) or 
200 mg/kg/day (groups H and HB). 
To induce fibrotic changes in the lungs of mice in 
groups CB, LB, and HB, BLM (150 mg/kg) was in-
travenously administrated via a tail vein under anes-
thesia with intraperitoneal injection of thiopental so-
dium (150mg/kg) on day 0. As a control, physiologi-
cal salt solution was infused intravenously infused in 
the groups C, L, and H. All animals were fed the same 
diet from day -2 to day 28. Thus, the mice were killed 
at 7 and 28 days after BLM treatment with excess 
thiopental sodium (450 mg/kg i.p.). Thorax was 
opened, and lungs were removed for histological 
studies. 
Table 1. Characteristics of subjects. 
Group Descrip-
tion 
Group 
Name 
Vesnarinone 
(mg/kg) 
Bleomycin 
(mg/kg) 
Number 
of Mouse
Control C  -  - 18 
Low dose  L  100*  -  18 
High dose  H  200**  -  18 
Control-bleomycin CB  -  150  24 
Low 
dose-bleomycin 
LB 100*  150  24 
High 
dose-bleomycin 
HB 200**  150  24 
*Estimated dose based on 0.083% vesnarinone in the diet. 
**Estimated dose based on 0.165% vesnarinone in the diet. 
Plasma Concentration of Vesnarinone 
Plasma concentrations of vesnarinone were 
measured on the 7  day of the oral administration. 
Under anesthesia, whole blood was obtained by direct 
puncture of right ventricle. Plasma was isolated by 
centrifugation (3000 rpm) and the concentrations of 
vesnarinone were determined by high-performance 
liquid chromatography as previously described [14]. 
Bronchoalveolar Lavage (BAL) 
We performed BAL on 5 to 8 mice in each group 
on 7 days after the bleomycin infusion. Under anes-
thesia with intraperitoneal thiopental sodium (150 
mg/kg), a 16-gauge canula was wedged into the tra-
chea. 3 ml of phosphate-buffered saline (PBS) was 
infused into the canula and was recovered, gently to 
avoid artificial lung injury due to hyperinflation. Cy-
tological preparations were made using centrifuga-
tion (Cytospin 2; Shandon, Pittsburgh, PA), and were 
stained with modified May-Giemsa stain (Diff Quick; 
American Science Products, McGaw Park, IL). Dif-
ferential all counts were performed on 200 cells per 
sample. Cells were also gathered from bronchoalveo-
lar lavage fluids (BALF) by centrifugation at 200 × g 
for 10 min, and its supernatants were stored at -80°C 
until evaluation. 
Biochemical Analysis of BALF and Plasma 
Total protein levels were evaluated by modified 
Bradford method [15]. Since tumor necrosis factor 
(TNF)-α, KC, and macrophage inflammatory pro-
tein-2 (MIP-2) are mediators of tissue injury and re-
pair and associated with lung fibrosis, Murine TNF-α  
(Quantikine; R&D Systems, Minneapolis, MN), mur-
ine KC, murine MIP-2, murine soluble TNF-receptor 
55 (sTNF-R55), and murine soluble TNF-receptor 75 
(sTNF-R75) (all from R&D Systems, Minneapolis, 
MN) in BALF and plasma were measured by an en-
zyme-linked immunosorbent assay (ELISA). Hyalu-
ronic acid, which increases in lung injury including 
fibrotic lung diseases, were quantified using en-
zyme-linked hyaluronic acid binding protein method 
(Read Medical Products inc., Westminster, CO). The 
albumin concentration in BALF was also determined 
by ELISA (Albuwell; Exocell Inc., Philadelphia, PA). 
Histological Analysis 
On day 28, both lungs were fixed by an infla-
tion-fixation method in 10% buffered formaldehyde 
under constant positive pressure (10 cm water pres-
sure) in preparation for histological examination [16]. 
The fixed lungs were sectioned sagittally, embedded 
in paraffin, and stained air way with Elastica-Masson 
or hematoxylin-eosin. For the area analysis of fibrotic 
changes, a quantitative fibrotic scale (Ashcroft scale) 
was used [16]. A numerical fibrotic score (Ashcroft 
scale) was obtained as follows; the severity of the fi-
brotic changes in each lung section was given as the 
mean score from the observed microscopic fields. 
M o r e  t h a n  2 5  f i e l d s  w i t h i n  e a c h  l u n g  s e c t i o n  w e r e  
observed at a magnification of ×100, and each field 
was assessed individually for severity and allotted a 
score from 0 (normal) to 8 (total fibrosis). The severity Int. J. Biol. Sci. 2009, 5 
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score for each field were averaged and are presented 
as the average for each lung section. To avoid bias, all 
histologic specimens were evaluated in a blinded 
fashion. Each specimen was scored independently by 
two observers, including a histopathologist; finally, 
the mean of their individual scores was taken as the 
fibrotic score.   
Hydroxyproline Assay 
On day 28, to estimate total lung collagen con-
tent, hydroxyproline was measured according to a 
method previously described with modifications [17]. 
Briefly, the lung was gently perfused with 3 ml of PBS 
from the right ventricle. Both lungs were then excised 
and homogenized (Tissue Tearor; Biospec Products, 
Inc., Bartlesville, OK) in 2 ml of PBS. 1 ml aliquot was 
desiccated using a rotary vacuum pump (Savant In-
struments, Inc., Farmingdale, NY) and then hydro-
lyzed in 6 N HCl at 110°C for 12 hr. Next, 50-μl ali-
q u o t s  w e r e  a d d e d  i n t o  1  m l  o f  1 . 4 %  c h l o r a m i n e  T  
(Sigma Chemical Co., St. Louis, MO), 10% n-propanol, 
and 0.5 M sodium acetate (pH 6.0). After 20 min of 
incubation at room temperature, 1 ml of Erlich’s solu-
tion (1 M p-dimethylaminobenzaldehyde in 70% 
n-propanol, 20% perchloric acid) was added and al-
lowed to incubate at 65°C for 15 min. Finally, the level 
of absorbance was measured at 550 nm using the 100 
μl of reaction product and the amount of hy-
droxyproline was determined against a standard 
curve generated using known concentrations of hy-
droxyproline (Sigma Chemical Co.).  
Statistical Analysis 
Results are reported as mean + SEM. The data 
from each subject were first compared using 
Kruskal-Wallis nonparametric one-way analysis of 
variance. When significant, the differences between 
the groups were further compared using nonpara-
metric Mann-Whitney U tests and the Steel-Dwass 
test with an adjustment of the p values (p<0.05). Cor-
relations were tested by calculating the Spearman 
correlation coefficient. P <0.05 was taken as the level 
of statistical significance. 
Results 
Plasma Concentrations of Vesnarinone 
We confirmed the lowest concentration of 
vesnarinone to be about 2 μg/ml in plasma from the L 
and LB groups (Fig. 1). Higher concentrations of 
vesnarinone were also detected in both the H and HB 
groups (Fig. 1). These levels were half of the plasma 
concentrations seen clinically when given to patients 
at a dose of 30 mg/day for the treatment of congestive 
heart failure [18]. 
 
 
Figure 1. Mouse plasma concentrations of vesnarinone on 
Day 7 after bleomycin treatment (C; n=5, L; n=5, H; n=5, 
CB; n=5, LB; n=5, HB; n=5). Data shown are means + SE.  
Analysis of BALF 
As shown in Table 2, total cell counts in BALF 
were significantly high on 7 days after BLM treatment 
(group CB) when these were compared with those 
from control group (group C; p<0.01). Significant in-
creases in macrophages, lymphocytes and neutrophils 
were also noted in BALF from group CB (p<0.01). 
Importantly, oral intake of vesnarinone at both doses 
reduced these increases in cell numbers of all cell 
types in group CB. Oral intake of vesnarinone alone 
(groups L and H) showed no change in the cellular 
profiles in BALF of group C. 
Table 2. Cell concentration in BALF 7 days after BLM administration. 
  Total cell (×104/ml) Macrophages  (×104/ml) Neutrophils (×104/ml) Lymphocytes 
(×104/ml) 
Total Protein 
(mg/ml) 
Albumin 
(mg/ml) 
C 10.0  + 1.7  10.0 + 1.7  0.00 + 0.0  0.00 + 0.0  118.0 + 33.5  23.4 + 4.4 
L 4.67  + 1.0  4.47 + 0.9  0.06 + 0.0  0.14 + 0.1  101.2 + 22.7  23.1 + 2.5 
H 5.33  + 0.8  5.18 + 0.8  0.09 + 0.0  0.06 + 0.0  91.6 + 15.1  23.1 + 2.5 
CB 37.7  + 2.9  34.3 + 2.6  1.90 + 0.4  1.50 + 0.2  2251 + 529  168.0 + 18.5 
LB 22.0  + 2.6**  20.6 + 2.4**  0.71 + 0.2**  0.66 + 0.1**  741.3 + 138**  90.6 + 12.0** 
HB 19.4  + 2.2**  18.6 + 2.2**  0.62 + 0.2**  0.22 + 0.1**  664.4 + 100**  108.1 + 16.0** 
C; n=6, L; n=6, H; n=6, CB; n=8, LB; n=8, HB; n=8. Data are shown as mean + SE. 
**p<0.01 compared with group CB 
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Total protein and albumin contents in BALF 
were increased after BLM treatment (group CB) (Ta-
ble 2). This increase was significantly inhibited by 
vesnarinone.  
The levels of KC, sTNF-R55, sTNF-R75, and 
hyaluronic acid in groups LB and HB were markedly 
suppressed (p<0.01) as compared with group CB (Ta-
ble 3). 
 
Table 3. Cytokine and chemokine in BALF, 7 days after 
BLM administration. 
 TNF-α (pg/ml) KC 
(pg/ml) 
MIP-2 
(pg/ml) 
sTNF-R55 
(pg/ml) 
sTNF-R75
(pg/ml) 
Hyaluronic 
acid 
(ng/ml) 
C 2.2  + 2.2  0.0 + 
0.0 
0.5 + 
0.3 
32.6 + 
16.8 
134.4 + 
16.6 
2.0 + 1.3 
L 4.1  + 2.7  0.0 + 
0.0 
0.7 + 
0.3 
15.0 + 7.4  145.6 + 
11.8 
3.3 + 3.3 
H 0.0  + 0.0  1.2 + 
1.2 
1.2 + 
0.5 
0.0 + 0.0  223.3 + 
40.1 
0.0 + 0.0 
CB 11.0  + 3.1  31.6 + 
5.5 
0.6 + 
0.3 
105.6 + 
14.0 
3486 + 
476 
493.1 + 200
LB 13.6  + 2.5  7.5 + 
2.6** 
0.6 + 
0.3 
33.4 + 
10.4** 
1497 + 
357** 
159.2 + 
87.2* 
HB 5.9 + 2.5  9.9 + 
2.0** 
0.4 + 
0.2 
52.8 + 
15.4** 
223 + 
40.1** 
128.0 + 
64.3* 
C; n=5, L; n=5, H; n=5, CB; n=8, LB; n=8, HB; n=8. Data are shown 
as mean + SE.   
**p<0.01 compared with CB, *p<0.05 compared with group CB 
 
Histologic Finding and Morphometry of Fibrosis 
There were no pathological changes in lungs 
from group C (Fig. 2A). In samples 4 weeks after the 
treatment revealed focal fibrotic lesions primarily in 
the subpleural and occasionally in the perivascular 
areas with consolidation of lung parenchyma, loss of 
alveolar architecture, and increased cellularity with 
alveolar macrophages (Fig. 2B). 
In contrast to the findings in mice treated with 
BLM alone, histologic findings at 4 weeks with si-
multaneous administration of vesnarinone revealed 
that fibrotic lesions were less focal in the subpleural 
areas, and fibrotic changes were milder in degree than 
in mice treated with BLM alone (Fig. 2C). 
The overall level of the fibrotic change was 
quantified by the numerical score (Ashcroft score). 
The scores in groups CB and HB were 1.4 + 0.4 and 0.7 
+ 0.1, respectively. A significant difference in the 
scores between two groups was demonstrated (Fig. 3). 
 
 
 
 
 
 
 
 
Figure 2. Representative histological findings of the lungs 
from control mouse (A: group C, n=4), mouse treated with 
bleomycin alone (B: group CB, n=6), and bleomycin-treated 
mouse with simultaneous administration of vesnarinone (C: 
group HB, n=6). Int. J. Biol. Sci. 2009, 5 
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Figure 3. Quantitative evaluation of fibrotic changes 
(Ashcroft scale) treated with bleomycin and vesnarinone. 
Fibrotic score (Ashcroft score) was obtained with a con-
tinuous numerical scale for determining the degree of fi-
brotic changes. Each grade was scored on a scale from 0 to 
8, and the average of microscopic field scores was used for 
comparison (x 100). C; n=4, L; n=4, H; n=4, CB; n=6, LB; 
n=6, HB; n=6. Data shown are means + SE.  
Collagen Content  
Collagen content was assessed by measuring 
hydroxyproline in the total lungs 4 weeks after BLM 
treatment. The hydroxyproline levels in BLM-treated 
lungs (group CB) were significantly increased from 
control mice (group C). The hydroxyproline content 
was lower in lungs treated with BLM and vesnarinone 
(group LB and HB) than in lungs treated with BLM 
alone (group CB) (Fig. 4). Mice treated with saline and 
vesnarinone (group L, H) showed minor increases in 
pulmonary hydroxyproline content compared with 
control mice (group C), although no statistical sig-
nificance was found.  
 
 
Figure 4. Hydroxyproline content in bleomycin and 
vesnarinone-treated lungs. To evaluate total lung collagen, 
hydroxyproline was extracted from lungs of mouse. C; n=5, 
L; n=5, H; n=5, CB; n=5, LB; n=5, HB; n=5. Data are shown 
as mean + SE. 
Circulating Hyaluronic Acid Levels 
Plasma hyaluronic acid contents were signifi-
cantly increased in mice treated with BLM alone, re-
flecting fibrotic changes in the lungs (Fig. 5). Oral 
administration of vesnarinone ameliorated these lev-
els in BLM-treated mice. 
 
 
Figure 5. Mouse plasma concentrations of hyaluronic acid 
on Day 28. Levels of hyaluronic acid in plasma of each 
mouse were quantified using enzyme-linked hyaluronic acid 
binding protein method. C; n=12, L; n=12, H; n=12, CB; 
n=12, LB; n=12, HB; n=12. Data are shown as mean + SE. 
Discussion 
In the present study, we investigated whether 
vesnarinone, a potential cytokine inhibitor, has a 
protective effect against the fibrotic changes induced 
by BLM administration in mice. Our study demon-
strated that vesnarinone inhibited the acute lung in-
juries, possibly by blocking the production of KC, and 
ameliorated the development of pulmonary fibrosis, 
since it is well known that the degree of the pulmo-
nary fibrosis is dependent on the severity of initial 
lung injury [19, 20]. Although inhibition of cytokine 
production by vesnarinone has been shown in various 
models [10, 12, 21-25], little is known about the use of 
vesnarinone for the treatment of lung injury or the 
development of pulmonary fibrosis. 
In 7 days after BLM treatment, elevated levels of 
cell numbers of all kinds of inflammatory cells, and 
protein and albumin contents in BALF were noted in 
CB group. Both low and high doses of vesnarinone 
intake significantly decreased all these levels. In ad-
dition, biochemical markers for lung inflammation in 
BALF including a neutrophilic chemokine, KC, 
sTNF-Rs, and hyaluronic acids, all which were in-
creased in CB mice, were decreased in LB and HB 
mice. These data clearly supported the anti-cytokine 
and chemokine activities of vesnarinone [10, 12, 
2 1 - 2 5 ] .  L e v e l s  o f  M I P - 2  i n  B A L F  w e r e  n o t  d i f f e r e n t  
among the groups. This data suggested that some Int. J. Biol. Sci. 2009, 5 
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restricted chemokines are involved in the early in-
flammation of BLM-induced lung injury. 
Oral administration of vesnarinone did not sup-
press the levels of TNF-α in BALF (LB and HB mice). 
The similar result was reported in a study in which 
acute lung injury caused by lipopolysaccharide and 
zymosan was suppressed by a type 4 PDE inhibitor, 
independent of TNF inhibition [26]. Levels of two 
sTNF-Rs, which are thought to inhibit TNF activities, 
were significantly decreased in BALF compared with 
LB and HB mice. Decreased shedding of both type 
sTNF-Rs may reflect the inhibition of the acute lung 
injuries induced by BLM, since a variety of inflam-
matory stimuli—including cytokines, oxidants, and 
protease—are known to shed sTNF-Rs [27, 28]. 
In 28 days after BLM administration, our patho-
logical data demonstrated that dietary intake of the 
high dose, but not the low dose, of vesnarinone sig-
nificantly reduced the pathological fibrotic changes 
induced by BLM. In contrast, the levels of both hy-
droxyproline and hyaluronic acid in lung tissue were 
significantly decreased in LB and HB mice than in CB 
mice. These differences in the inhibitory capacity 
between LB and HB mice may be explained by the fact 
that lung morphological changes (Ashcroft score) do 
not always parallel the changes in biochemical mark-
ers (hydroxyproline and hyaluronic acid content) in 
the pulmonary fibrosis [29]. 
Vesnarinone has a variety of functions including 
the inhibition of PDE3, increased inward calcium flux, 
reduced potassium flux, and a novel cytokine inhib-
iting activity [12, 21-25]. In addition, vesnarinone is 
reported to inhibit the increase in natural killer cell 
activity after viral infection [12]. Vesnarinone inhibits 
E-selectin expression in human umbilical vein endo-
thelial cells [30]. Since nitric oxide is one of the im-
portant mediators responsible for the development of 
lung injury, vesnarinone may ameliorate 
BLM-induced lung injury by inhibiting the induction 
of nitric oxide syntheses [22, 23]. Furthermore, a re-
cent study has demonstrated that vesnarinone inhibits 
the secretion of hyaluronan in myofibroblasts by spe-
cifically suppressing hyaluronan synthase activity 
[31]. All these anti-inflammatory effects of vesnari-
none may play roles in the inhibition of BLM-induced 
lung injury. Although amelioration of experimental 
acute lung injury has been reported using a nonspe-
cific PDE inhibitor, pentoxyfylline [32], and a PDE4 
inhibitor, rolipram [26], vesnarinone may have a spe-
cific activity for the suppression of cytokine produc-
tion [10, 12, 21-25]. Since the degree of the pulmonary 
fibrosis is closely related to the severity of initial acute 
lung injury in patients with acute respiratory distress 
syndrome [19, 20], vesnarinone would ameliorate the 
development of pulmonary fibrosis due to the sup-
pression of BLM-induced acute lung injury. However, 
precise mechanisms of amelioration of BLM-induced 
pulmonary fibrosis by vesnarinone remain to be elu-
cidated. 
Unique activities of vesnarinone including inhi-
bition of Fas expression and apoptosis [24] may also 
ameliorate fibrotic change in mice since ligation of Fas 
antigen induces apoptosis in lung epithelial cells and 
develops pulmonary fibrosis [33]. Thus it is possible 
that vesnarinone ameliorates fibrotic changes by in-
hibiting apoptosis in lung epithelial cells. Addition-
ally, it has been reported that vesnarinone has anti-
proliferative effects and apoptosis-inducing activities 
in various tumor cells. Since these effects are related 
to known activities of vesnarinone, which induces a 
negative growth factor, TSC-22 [34], or a cy-
clin-dependent kinase inhibitor, p21WAF1 [35] and in-
hibits expression of interleukin-8 [36], the inhibition of 
fibroblast growth may be mediated by these mecha-
nisms in the development process on BLM-induced 
pulmonary fibrosis.   
In conclusion, vesnarinone is one of the potential 
therapeutic agents for the treatment of lung fibrosis. 
Further experiments will be required to understand 
how this drug reduces the fibrotic response. 
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